H.C. Wainwright analyst Brandon Folkes assumed coverage of Valneva (VALN) with a Buy rating and $18 price target The firm says Valneva is a commercial-stage vaccine company with a “strong proprietary portfolio.” VLA15 offers a “de-risked, relatively high-probability path” to potential blockbuster sales, the analyst tells investors in a research note.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VALN:
- Valneva’s Chikungunya Vaccine IXCHIQ® Gains Health Canada Approval
- Valneva SE Reports Strong Revenue Growth in 2025
- Valneva Reports Strong Revenue Growth and Strategic Advances in H1 2025
- VALN Earnings this Week: How Will it Perform?
- Valneva’s Chikungunya Vaccine IXCHIQ® Resumes Use for Elderly After FDA Approval